Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 46 Show results per page	View Search Criteria \| Help With Results


1.		The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Completed				18 and over				Pharmaceutical / Industry				CZOL446GUS45 ZENITH, NCT00063609


2.		A Multiple Myeloma Trial in Patients With Bone Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				CZOL446EUS97 US97, NCT00104104


3.		Zoledronic Acid in the Prevention of Skeletal-Related Events in Hormone Refractory and Hormone-Sensitive Prostate Cancer Patients With Bone Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Completed				18 to 120				Pharmaceutical / Industry				CZOL446EIT04 NCT00219219


4.		Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 to 80				Pharmaceutical / Industry				CZOL446GGR01 NCT00219271


5.		Evaluation of the Efficacy and Tolerability of Zoledronic Acid in Combination With Radiotherapy in Patients With Advanced Osteolytic Bone Lesions

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				CZOL446EDE06 NCT00171964


6.		Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Closed				18 to 75				Other				CZOL446ECN05 NCT00524849

Last Modified: 11/1/2001 First Published: 5/1/1999


7.		Phase III Randomized Study of Zoledronate Versus Pamidronate in Patients With Cancer-Related Bone Lesions Due to Multiple Myeloma or Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-4244603010 UCLA-9911015

Last Modified: 5/31/2007 First Published: 7/1/1999


8.		Phase III Randomized Study of Zoledronate With or Without Antineoplastic Therapy in Patients with Any Solid Tumor with Bone Metastases Other than Breast Cancer or Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-4244603011 NCT00003884

Last Modified: 10/20/2007 First Published: 7/1/1999


9.		Phase III Randomized Study of Zoledronate in Patients With Bone Metastases Secondary to Prostate Cancer (Summary Last Modified 12/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-4244603039

Last Modified: 11/12/2007 First Published: 4/1/2000


10.		Phase III Randomized Study of Zoledronate and Standard Therapy vs Placebo and Standard Therapy in Patients With Asymptomatic Recurrent Prostate Cancer Who Have Castrate Levels of Testosterone and Rising PSA Levels

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				UCLA-9908030 NOVARTIS-CZOL4460704, NCI-G00-1722, NCT00005073

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute